The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

A compound has retinoid-related orphan receptor ? antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof.

##STR00001##

Provided are novel compounds of Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.

Provided herein are Purine Comounds of Formula (I) ##STR00001## or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, Q.sup.1, Q.sup.2, Y.sup.1, and Y.sup.2 are as defined in the disclosure; and T is J.sup.1-A- and also as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, Q.sup.1, Q.sup.2, Y.sup.1, and Y.sup.2 are as defined in the disclosure; and T is J.sup.1-A- and also as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.